MARKET WIREChartMill • 1d ago
Postmarket Movers: After-Hours Gainers and LosersAfter-hours movers: INOVIO jumped 283.0% and Glucotrack dropped 57.19%, among the largest postmarket gainers and losers.
Why TSHA Stock slipped -0.24% Today — RQD Quant Desk Flash
$4.22 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.21
Taysha Gene Therapies Inc. (TSHA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $1.38B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.21 (-0.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TSHA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY TSHA SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)
Altman Z-Score 5.67 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$4.49-19.4% Next Q
51
Q2 (-2Q)Grade D$3.62+9.4% Next Q
48
Q3 (-1Q)Grade D$3.96+6.6% Next Q
46
CurrentGrade D-$4.22-6.7% Hist 90D α
43
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TSHA Turnaround Squeeze
While TSHA currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.82) and Max Pain ($4.43) forces dealer call-delta covering toward $7.67.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TSHA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TSHA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TSHA Stock slipped -0.24% Today — RQD Quant Desk Flash
Taysha Gene Therapies Inc. (TSHA) slipped -0.24% to $4.22, trading at 20% of its 52-week range ($3.46 – $7.3). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 20% of its 52-week range ($3.46 – $7.3) with RSI-14 at 43.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.22 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TSHA Headlines & Catalysts
MARKET WIREYahoo • 2d ago
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book ValueTaysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its ba
MARKET WIREYahoo • 13d ago
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-relat
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TSHA)
- ✓Walkthrough of TSHA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TSHA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.96%▼ DESCENDING CHANNEL
2026-10-30O $4.18H $4.25L $4.07C $4.22VOL 1.50M
RES: $6.02SUP: $3.05SMA50: $4.82SMA200: $5.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TSHA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TSHA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TSHA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TSHA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TSHA)
Health Care Rank #542 of 1016
⚔️ LYCA vs TSHA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TSHA vs. LYCA, VOR, IMCR, REPL)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Taysha Gene Therapies Inc. (TSHA) ranks #542 by composite RQD confidence (43/100, grade D-) and #316 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, TSHA leads on earnings valuation at N/A trailing P/E, while TSHA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with TSHA at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TSHA
ACTIVE
Taysha Gene Therapies Inc. | D- | 43/100 | — | — | -35.0% | -0.24% | $1.38B | Benchmark Subject |
| LYCA Lycia Therapeutics Inc. | C- | 59/100 | — | — | — | +10.70% | $1.44B | /lyca-vs-tsha → |
| VOR Vor Biopharma Inc. | D- | 37/100 | — | — | -35.0% | +1.26% | $1.24B | /vor-vs-tsha → |
| IMCR Immunocore Holdings plc | E | 31/100 | — | 96.0% | -35.0% | -4.11% | $1.61B | /imcr-vs-tsha → |
| REPL Replimune Group Inc. | D | 46/100 | — | — | -35.0% | +8.28% | $1.65B | /repl-vs-tsha → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001806310In its most recent audited fiscal period (FY2025, filed 2025-12-31), Taysha Gene Therapies Inc. (TSHA) reported GAAP revenue of $9.8M (+17.3% vs. FY2024 revenue of $8.3M , and -36.7% cumulative change since FY2023) , GAAP net income of -$109.0M, operating cash flow of -$93.1M, and free cash flow of -$93.8M (-15.0% YoY). On the balance sheet, TSHA closed FY2025 with $343.3M in total assets against $50.1M in total debt (Altman Z-Score: 5.67, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.8M | -$109.0M | -$93.1M | -$93.8M | $343.3M | $50.1M |
| FY2024 (FY) | 2024-12-31 | $8.3M | -$89.3M | -$81.2M | -$81.6M | $160.4M | $43.9M |
| FY2023 (FY) | 2023-12-31 | $15.5M | -$111.6M | -$73.0M | -$73.0M | — | — |
3. TSHA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TSHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Taysha Gene Therapies Inc. (NASDAQ: TSHA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.22 (-0.24% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TSHA ranks #542 in composite RQD confidence.
How does TSHA compare to LYCA and VOR in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TSHA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYCA (Lycia Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $1.44B) and VOR (Vor Biopharma Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.24B). Among the 5-stock peer group, TSHA leads on earnings multiple (N/A) while TSHA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TSHA?
Per TSHA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001806310), Taysha Gene Therapies Inc. generated $9.8M in revenue (+17.3% YoY), -$109.0M in net income, and -$93.8M in free cash flow against $343.3M in total assets and $50.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TSHA trading relative to its 50-day, 200-day, and 52-week technical levels?
TSHA last traded at $4.22 (-0.24% on volume of 2,057,824 shares), positioning the stock -12.45% below its 50-day simple moving average ($4.82) and -20.68% below its 200-day simple moving average ($5.32). Across its 52-week range of $3.46 to $7.30, TSHA sits at the 19.8% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.69 to $4.75).
TSHA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TSHA stock moving today?
Why TSHA Stock slipped -0.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.